News

Filter

Current filters:

nivolumabGlobal

B-MS' nivolumab to lead NSCLC market with sales of $1.75 billion by 2022, says GlobalData

08-07-2013

US pharma major Bristol-Myers Squibb's (NYSE: BMY) nivolumab will overtake proven blockbuster competitors…

Bristol-Myers SquibbGlobalMarkets & MarketingnivolumabOncologyPharmaceutical

Prognosis for renal cell carcinoma market development

27-11-2012

Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug…

Bristol-Myers SquibbGlaxoSmithKlineGlobalMarkets & MarketingnivolumabOncologyPfizerPharmaceuticalSutentVotrient

COMPANY SPOTLIGHT

Menarini

Back to top